Expert Ratings for BridgeBio Pharma
Portfolio Pulse from Benzinga Insights
Over the past 3 months, 4 analysts have published their opinion on BridgeBio Pharma (NASDAQ:BBIO) stock. The average 12-month price target for the stock is $39.5, with a high of $50.00 and a low of $29.00. This average price target has increased by 50.48% over the past month.
July 18, 2023 | 1:01 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Analysts have a positive outlook on BridgeBio Pharma (NASDAQ:BBIO) stock with an increasing average 12-month price target.
The increasing average 12-month price target indicates that analysts have a positive outlook on the stock. This could potentially lead to an increase in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100